Search by Drug Name or NDC
NDC 70710-1839-01 Nelarabine 5 mg/mL Details
Nelarabine 5 mg/mL
Nelarabine is a INTRAVENOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Zydus Pharmaceuticals USA Inc.. The primary component is NELARABINE.
MedlinePlus Drug Summary
Nelarabine is used to treat certain types of leukemia (cancer that begins in the white blood cells) and lymphoma (cancer that begins in the cells of the immune system) that have not improved or that have come back after treatment with other medications. Nelarabine is in a class of medications called antimetabolites. It works by killing cancer cells.
Related Packages: 70710-1839-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Nelarabine Injection
Product Information
NDC | 70710-1839 |
---|---|
Product ID | 70710-1839_7b0a1790-c6e3-4f09-859f-1ae9db46b007 |
Associated GPIs | |
GCN Sequence Number | 059981 |
GCN Sequence Number Description | nelarabine VIAL 250MG/50ML INTRAVEN |
HIC3 | V1B |
HIC3 Description | ANTINEOPLASTIC - ANTIMETABOLITES |
GCN | 25932 |
HICL Sequence Number | 033304 |
HICL Sequence Number Description | NELARABINE |
Brand/Generic | Generic |
Proprietary Name | Nelarabine |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Nelarabine |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION |
Route | INTRAVENOUS |
Active Ingredient Strength | 5 |
Active Ingredient Units | mg/mL |
Substance Name | NELARABINE |
Labeler Name | Zydus Pharmaceuticals USA Inc. |
Pharmaceutical Class | Nucleic Acid Synthesis Inhibitors [MoA], Nucleoside Metabolic Inhibitor [EPC] |
DEA Schedule | n/a |
Marketing Category | ANDA |
Application Number | ANDA215037 |
Listing Certified Through | 2024-12-31 |
Package
NDC 70710-1839-01 (70710183901)
NDC Package Code | 70710-1839-1 |
---|---|
Billing NDC | 70710183901 |
Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (70710-1839-1) / 50 mL in 1 VIAL, SINGLE-DOSE |
Marketing Start Date | 2022-06-24 |
NDC Exclude Flag | N |
Pricing Information | N/A |